基本信息
views: 12
Career Trajectory
Bio
His two main research interests are 1) maximizing oral bioavailability through formulation and chemical approaches and 2) developing public quality standards for oral dosage forms. He has published in the areas of dissolution, drug intestinal permeability, transporter substrate requirements, prodrug design, oral bioavailability, in vitro - in vivo correlation, and bioequivalence. Dr. Polli is a fellow of the American Association of Pharmaceutical Scientists, an Editorial Board member of several journals, an Editor of Pharmaceutical Research, and a member of the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee. He teaches professional pharmacy students and graduate students, and has served as advisor to 21 Ph.D. graduates.
Research Interests
Papers共 257 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2024): 106745-106745
Molecular pharmaceuticsno. 5 (2024): 2065-2080
European Journal of Pharmaceutical Sciences (2024): 106746-106746
David Plano, Niklas Rudolph,Christoph Saal,Bertil Abrahamsson,Rodrigo Cristofoletti,Atsushi Kambayashi,Peter Langguth,Mehul Mehta,Alan Parr,James E. Polli,Vinod P. Shah,Naseem Charoo,
JOURNAL OF PHARMACEUTICAL SCIENCESno. 2 (2024): 386-395
Journal of Pharmaceutical Sciences (2024)
Journal of pharmaceutical sciences (2024)
Journal of pharmaceutical sciences (2024)
Molecular pharmaceuticsno. 6 (2024): 2828-2837
Pharmaceutical Researchno. 6 (2024): 1-18
Load More
Author Statistics
#Papers: 266
#Citation: 8252
H-Index: 42
G-Index: 83
Sociability: 7
Diversity: 0
Activity: 3
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn